NOTUS Trial Confirms Dupixent Benefit in COPD with Type 2 Inflammation
Use of dupilumab reduced exacerbations and improved lung function in COPD patients with type 2 inflammation.
Source: hcplive.com
Page 7 - Priority Review News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Priority Review. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Priority Review Today - Breaking & Trending Today
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine
NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic...
Source: marketscreener.com
Dupixent® (dupilumab) Late-Breaking Data from NOTUS
NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function,...
Source: globenewswire.com
Sanofi: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly
Source: finanznachrichten.de
Galderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in Four Additional Countries
ZUG, Switzerland--(BUSINESS WIRE)--May 7, 2024--
Source: valdostadailytimes.com